GleamWall
中文EN

AMRN AMARIN CORP PLC\UK

Pharmaceutical Preparations · Nasdaq · SEC CIK 897448 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-22.3%
TTM net income YoY77.8%
TTM EPS YoY81.0%
Revenue 3-yr CAGR-18.3%
Net income 3-yr CAGR—

Margins

Gross margin40.9%
Operating margin-18.2%
Net margin-10.9%
FCF margin—
EBITDA margin—

Returns

ROE-4.2%
ROA-3.0%
ROIC (approx.)-8.1%
Asset turnover0.27x

Leverage & solvency

Liabilities / assets29.9%
Debt / equity0.00x
Current ratio3.50x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-1.96x
Accruals ratio-8.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$213.65M$228.61M
Gross profit$120.87M$81.38M
R&D expense$19.81M$20.87M
SG&A expense$115.00M$152.31M
Operating income-$50.17M-$91.80M
Interest expense$7,000$7,000
Pretax income-$36.05M-$77.20M
Income tax$2.75M$4.98M
Net income-$38.80M-$82.18M
EBITDA—-$91.70M
EPS (basic)-0.09-0.20
EPS (diluted)-0.09-0.20
Weighted avg. shares (diluted)414.98M410.94M
Balance sheet
Cash & equivalents$134.66M$121.04M
Short-term investments$167.93M$173.18M
Receivables$126.83M$122.28M
Inventory$195.91M$166.05M
Current assets$649.88M$595.40M
PP&E, net$12,000$16,000
Intangibles$13.37M$16.39M
Total assets$670.77M$685.35M
Current liabilities$194.46M$179.95M
Total liabilities$211.49M$199.17M
Shareholders' equity$459.28M$486.18M
Shares outstanding416.21M411.58M
Cash flow statement
Operating cash flow$6.73M-$31.02M
Investing cash flow$8.83M-$45.98M
Financing cash flow-$2.03M-$1.44M
Depreciation & amortization—$100,000
Stock-based compensation$13.94M$17.70M

Free plan shows the latest 2 periods; Pro shows all 20 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.